New Therapeutics in Alzheimer's Disease Longitudinal Cohort Study (NTAD): Study Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Dec 15

PMID 36521898

Authors

Juliette Helene Lanskey

Ece Kocagoncu

Andrew J Quinn

Yun-Ju Cheng

Melek Karadag

Jemma Pitt

Stephen Lowe

Michael Perkinton

Vanessa Raymont

Krish D Singh

Mark Woolrich

Anna C Nobre

Richard N Henson

James B Rowe

Affiliations

Soon will be listed here.

Abstract

Introduction: With the pressing need to develop treatments that slow or stop the progression of Alzheimer's disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophysiological measurements of disease.

Methods And Analysis: The New Therapeutics in Alzheimer's Disease study (NTAD) aims to identify a biomarker set from magneto/electroencephalography that is sensitive to disease and progression over 1 year. The study will recruit 100 people with amyloid-positive mild cognitive impairment or early-stage Alzheimer's disease and 30 healthy controls aged between 50 and 85 years. Measurements of the clinical, cognitive and imaging data (magnetoencephalography, electroencephalography and MRI) of all participants will be taken at baseline. These measurements will be repeated after approximately 1 year on participants with Alzheimer's disease or mild cognitive impairment, and clinical and cognitive assessment of these participants will be repeated again after approximately 2 years. To assess reliability of magneto/electroencephalographic changes, a subset of 30 participants with mild cognitive impairment or early-stage Alzheimer's disease will also undergo repeat magneto/electroencephalography 2 weeks after baseline. Baseline and longitudinal changes in neurophysiology are the primary analyses of interest. Additional outputs will include atrophy and cognitive change and estimated numbers needed to treat each arm of simulated clinical trials of a future disease-modifying therapy.

Ethics And Data Statement: The study has received a favourable opinion from the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Results will be disseminated through internal reports, peer-reviewed scientific journals, conference presentations, website publication, submission to regulatory authorities and other publications. Data will be made available via the Dementias Platform UK Data Portal on completion of initial analyses by the NTAD study group.

Citing Articles

Reliability of dynamic causal modelling of resting-state magnetoencephalography.

Jafarian A, Assem M, Kocagoncu E, Lanskey J, Williams R, Cheng Y Hum Brain Mapp. 2024; 45(10):e26782.

PMID: 38989630 PMC: 11237883. DOI: 10.1002/hbm.26782.

References

Hughes L, Henson R, Pereda E, Bruna R, Lopez-Sanz D, Quinn A . Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography. Alzheimers Dement (Amst). 2019; 11:450-462. PMC: 6579903. DOI: 10.1016/j.dadm.2019.04.009. View

Hughes L, Rowe J . The impact of neurodegeneration on network connectivity: a study of change detection in frontotemporal dementia. J Cogn Neurosci. 2013; 25(5):802-13. PMC: 3708294. DOI: 10.1162/jocn_a_00356. View

Kashyap G, Bapat D, Das D, Gowaikar R, Amritkar R, Rangarajan G . Synapse loss and progress of Alzheimer's disease -A network model. Sci Rep. 2019; 9(1):6555. PMC: 6484103. DOI: 10.1038/s41598-019-43076-y. View

Adams N, Hughes L, Phillips H, Shaw A, Murley A, Nesbitt D . GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography. J Neurosci. 2020; 40(8):1640-1649. PMC: 7046325. DOI: 10.1523/JNEUROSCI.1689-19.2019. View

Bennys K, Rondouin G, Benattar E, Gabelle A, Touchon J . Can event-related potential predict the progression of mild cognitive impairment?. J Clin Neurophysiol. 2011; 28(6):625-32. DOI: 10.1097/WNP.0b013e31823cc2d3. View

Ossenkoppele R, Schonhaut D, Scholl M, Lockhart S, Ayakta N, Baker S . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016; 139(Pt 5):1551-67. PMC: 5006248. DOI: 10.1093/brain/aww027. View

Chapman R, McCrary J, Gardner M, Sandoval T, Guillily M, Reilly L . Brain ERP components predict which individuals progress to Alzheimer's disease and which do not. Neurobiol Aging. 2009; 32(10):1742-55. PMC: 2902777. DOI: 10.1016/j.neurobiolaging.2009.11.010. View

Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

Faul F, Erdfelder E, Buchner A, Lang A . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4):1149-60. DOI: 10.3758/BRM.41.4.1149. View

10.

Adams N, Hughes L, Rouse M, Phillips H, Shaw A, Murley A . GABAergic cortical network physiology in frontotemporal lobar degeneration. Brain. 2021; 144(7):2135-2145. PMC: 8370432. DOI: 10.1093/brain/awab097. View

11.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

12.

Pinotsis D, Schwarzkopf D, Litvak V, Rees G, Barnes G, Friston K . Dynamic causal modelling of lateral interactions in the visual cortex. Neuroimage. 2012; 66:563-76. PMC: 3547173. DOI: 10.1016/j.neuroimage.2012.10.078. View

13.

Jutten R, Peeters C, Leijdesdorff S, Visser P, Maier A, Terwee C . Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst). 2017; 8:26-35. PMC: 5403784. DOI: 10.1016/j.dadm.2017.03.002. View

14.

Cai L, Innis R, Pike V . Radioligand development for PET imaging of beta-amyloid (Abeta)--current status. Curr Med Chem. 2007; 14(1):19-52. DOI: 10.2174/092986707779313471. View

15.

Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View

16.

Puttaert D, Coquelet N, Wens V, Peigneux P, Fery P, Rovai A . Alterations in resting-state network dynamics along the Alzheimer's disease continuum. Sci Rep. 2020; 10(1):21990. PMC: 7738511. DOI: 10.1038/s41598-020-76201-3. View

17.

Baker A, Brookes M, Rezek I, Smith S, Behrens T, Probert Smith P . Fast transient networks in spontaneous human brain activity. Elife. 2014; 3:e01867. PMC: 3965210. DOI: 10.7554/eLife.01867. View

18.

Lai C, Lin R, Liou L, Liu C . The role of event-related potentials in cognitive decline in Alzheimer's disease. Clin Neurophysiol. 2009; 121(2):194-9. DOI: 10.1016/j.clinph.2009.11.001. View

19.

Xu M, Sanz D, Garces P, Maestu F, Li Q, Pantazis D . A Graph Gaussian Embedding Method for Predicting Alzheimer's Disease Progression With MEG Brain Networks. IEEE Trans Biomed Eng. 2021; 68(5):1579-1588. PMC: 8162933. DOI: 10.1109/TBME.2021.3049199. View

20.

Leung K, Barnes J, Ridgway G, Bartlett J, Clarkson M, MacDonald K . Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage. 2010; 51(4):1345-59. PMC: 2873209. DOI: 10.1016/j.neuroimage.2010.03.018. View